Article Text

Download PDFPDF

Intradermal influenza vaccination in complete remission cancer patients: molecular insights
  1. Davide Bedognetti1,
  2. Maria Libera Ascierto1,
  3. Marimo Sato-Matsushita1,
  4. Elena Gugiatti2,
  5. Carlotta Massucco2,
  6. Simonetta Zupo2,
  7. Antonio Di Meglio2,
  8. Chiara Dellepiane2,
  9. Mario Roberto Sertoli2,
  10. Omar Racchi2,
  11. Enrico Balleari2,
  12. Valeria De Giorgi1,
  13. Michele Sommariva1,
  14. Paolo Durando2,
  15. Manlio Ferrarini2,
  16. Roberto Cacciani2,
  17. Nicoletta Provinciali2,
  18. Rocco Iudici2,
  19. Cristiano Alicino2,
  20. Ena Wang1,
  21. Filippo Ansaldi2,
  22. Francesco M Marincola3,1 and
  23. Andrea De Maria2
  1. Aff1 grid.420086.80000 0001 2237 2479DTM, NIH Bethesda MD USA
  2. Aff2 grid.410345.70000 0004 1756 7871IRCCS San Martino-Ist Genova Italy
  3. Aff3 grid.467063.00000000403974222Sidra Medical and Research Centre Doha Qatar

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

We previously showed that long-lasting complete remission (CR) non-Hodgkin lymphoma (NHL) patients treated with rituximab-containing chemotherapy have an attenuated antibody response to virosomal (Bedognetti et al, J. Immunology, 2011) or MF-59 adjuvanted (Bedognetti et al, Blood, 2012) seasonal (or pandemic) influenza vaccine (as compared with healthy controls), associated with persistent CD27+ Memory B cell depletion and hypogammaglobulinemia. Here, we evaluated humoral and innate response to trivalent intradermal vaccination in NHL in CR previously treated with rituximab-containing chemotherapy (at least one year before vaccine administration), RIT group, and in CR cancer patients treated with chemotherapy without rituximab (at least one year before vaccine administration), Non-RIT group. Intradermal administration was chosen considering its promising data, compared to conventional intramuscular route, in terms of immunogenicity and safety. Humoral response was assessed by hemagglutinin inhibition assay on sera collected at time 0 (just before vaccination) and at time 28 (four weeks after vaccination). Innate response was assessed by whole-genome gene expression analysis (Affymetrix Humane Gene ST 1.0) on PBMC collected at time 0 and at time 1 (24 hours after vaccine administration). Patients treated with rituximab-containing chemotherapy had, overall, a lower antibody response, compared to patients treated with chemotherapy alone. Overall, intradermal vaccination induced dramatic changes in gene-expression profile already one day after vaccination. These changes underline the activation of IFN stimulated genes (eg, STAT1, STAT2, CXCL10, IDO1, GBP1) and modulation of NK-associated transcripts. In addition, pathway and gene-enrichment analysis show that RIT and non-RIT groups have different quantitative and qualitative transcriptomic changes 24 hours after vaccination administration. Concordantly with antibody-titer, the innate response was more intense in Non-RIT group compared with RIT group.